U. Paulus

发表

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

V. Diehl, H. Müller-Hermelink, B. Dörken, 2003, The New England journal of medicine.

A dynamic model of proliferation and differentiation in the intestinal crypt based on a hypothetical intraepithelial growth factor

U. Paulus, M. Loeffler, T. Gerike, 1998, Cell proliferation.

A model of the control of cellular regeneration in the intestinal crypt after perturbation based solely on local stem cell regulation

U. Paulus, M. Loeffler, C. Potten, 1992, Cell proliferation.

Intestinal Crypt Proliferation. Ii. Computer Modelling of Mitotic Index Data Provides Further Evidence For Lateral and Vertical Cell Migration In the Absence of Mitotic Activity

U. Paulus, M. Loeffler, C. Potten, 1988, Cell and tissue kinetics.

Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

R. Greil, R. Müller, N. Willich, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

H. Eich, R. Müller, S. Sehlen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of Hematology.

Classical Hodgkin's disease. Clinical impact of the immunophenotype.

V. Diehl, K. Hübner, J. Franklin, 1997, The American journal of pathology.

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

R. Greil, V. Diehl, J. Franklin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems

N. Schmitz, U. Paulus, P. Dreger, 1997, Stem cells.

Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial

M. Hellmich, U. Paulus, H. Seifert, 2015, Trials.

Clonality and life cycles of intestinal crypts explained by a state dependent stochastic model of epithelial stem cell organization.

U. Paulus, M. Loeffler, C. Potten, 1997, Journal of Theoretical Biology.

Scoring Mitotic Activity In Longitudinal Sections of Crypts of the Small Intestine

U. Paulus, M. Loeffler, S. Chwalinski, 1988, Cell and tissue kinetics.

The crypt cycle in mouse small intestinal epithelium.

U. Paulus, M. Loeffler, S. Roberts, 1994, Journal of Cell Science.

The differentiation and lineage development of goblet cells in the murine small intestinal crypt: experimental and modelling studies.

J. Zeidler, U. Paulus, M. Loeffler, 1993, Journal of cell science.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials

Christian Ohmann, Gabriele Schwarz, Ursula Paulus, 2009, Clinical trials.

Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL

N. Schmitz, U. Paulus, P. Dreger, 1997, Bone Marrow Transplantation.

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

U. Paulus, J. Glossmann, A. Engert, 2002, Annals of Hematology.

Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group.

U. Paulus, J. Wolf, P. Schiller, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[German Hodgkin's Lymphoma Study Group].

V. Diehl, U. Paulus, J. Wolf, 2001, Onkologie.

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, U. Paulus, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, M. Pfreundschuh, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost of illness of malignant lymphoma in Germany.

V. Diehl, U. Paulus, V Diehl, 2006, European journal of cancer care.

Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?

U. Paulus, M. Löffler, C. Terschüren, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.

R. Greil, N. Willich, V. Diehl, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study

Dirk Hasenclever, Gabriele Schwarz, Ursula Paulus, 2017, Clinical trials.